LLYHEALTHCAREFree preview

Eli Lilly and Company

Last close: $1364.73Last updated: Nov 6, 2026

LLY

— Eli Lilly and Company

INDUSTRY:DRUG MANUFACTURERS - GENERAL
SECTOR:HEALTHCARE

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

OVERALL AI RATING

69/100

BULLISH

81% confidence · 9 of 9 factors

Higher when more factors have data and they agree with each other.

Bullish outlook primarily supported by favorable historical monthly trends.

FUNDAMENTALS OUTLOOK

67

/100

Favorable

+4% vs the model's 6-month fair value; ranks in the bottom 48% of mega caps by model upside.

Valuation against the model's 6-month target, reported financials, analyst consensus, and the earnings beat streak. P/E versus this company's own history is shown for reference.

Fair Value

38% of score

+3.9% vs fair value (48th pct of mega caps)

Fundamentals

15% of score

revenue +28%, margin 54%, FCF yield +1.6%

P/E vs History

informational · no weight

P/E 42.7 vs 37.6 avg (+0.2σ)

Analyst Consensus

10% of score

consensus

Earnings Beat Streak

4% of score

6 straight beats

SEASONALITY OUTLOOK

75

/100

Strong

The seasonal model expects +8.1% over 90 days and +3.1% over 30 days.

The seasonal price model at both scored horizons.

Seasonal Forecast · 90d

25% of score

+8.1% expected

Seasonal Forecast · 30d

5% of score

+3.1% 30d

TECHNICAL OUTLOOK

50

/100

Neutral

Annualized volatility 28%. Chart signal reads Hold (shown for reference, no weight in the score).

The volatility penalty. The chart classifier's short-horizon read is shown for reference but no longer weighs on the score.

Chart Signal

informational · no weight

-0.05

Volatility

4% of score

0.28 ann.

How the rating is built: each factor's weight × signal is its contribution. The contributions add up to a raw score from −100 to +100, and the overall score is 50 plus half that sum. A factor with no data counts as neutral, so it neither helps nor hurts.

Fair Value

38% of score

How far today's price sits from the model's 6-month fair value estimate, ranked against companies of similar size.

+3.9% vs fair value (48th pct of mega caps)

-1.6

Seasonal Forecast · 90d

25% of score

The seasonal price model projected 90 days out, as an expected return. It reads this stock's own price history and repeating calendar cycles — not company news, earnings, or business quality. Same model as the 30-day factor below, read at a longer horizon.

+8.1% expected

+13.4

Chart Signal

informational · no weight

A machine-learning classifier reading momentum and trend structure across daily and weekly price bars. Needs about 5 years of trading history. Shown for information only: it reads roughly five days ahead, shorter than the score's horizon, so it carries no weight in the AI Score.

-0.05

+0.0

Fundamentals

15% of score

Reported results, not projections: revenue growth, operating margin, and free cash flow measured against market value. Loss-making or cash-burning companies score negative here.

revenue +28%, margin 54%, FCF yield +1.6%

+11.0

P/E vs History

informational · no weight

Today's price-to-earnings against this company's own trailing average, in standard deviations. Needs positive earnings. Shown for information only: tested on ten years of history it did not improve the score, so it carries no weight.

P/E 42.7 vs 37.6 avg (+0.2σ)

+0.0

Analyst Consensus

10% of score

Wall Street consensus ratings, weighted by conviction.

consensus

+9.4

Seasonal Forecast · 30d

5% of score

The same seasonal price model as the 90-day factor above, read 30 days out. A near-term and a medium-term view of one forecast, which is why they can disagree.

+3.1% 30d

+1.6

Earnings Beat Streak

4% of score

How many quarters in a row this company has beaten analysts' earnings estimates. Four or more in a row counts fully; not beating the estimate last quarter counts against it.

6 straight beats

+3.8

Volatility

4% of score

An annualized volatility penalty. High volatility lowers the score; low volatility never raises it.

0.28 ann.

+0.0

Reader questions

Questions about LLY

Is LLY overvalued or undervalued right now?

As of Oct 30, 2026, ŷRobot's fair-value model estimates Eli Lilly and Company (LLY) at $1417.75 against a last close of $1364.73, implying 3.9% upside to the model's estimate.

Is LLY's chart signal bullish or bearish?

The chart-signal model classifies LLY as Neutral as of Nov 6, 2026, with a signal score of -0.05 on a -1 to 1 scale.

What is LLY's ŷRobot AI score?

LLY scores 69 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 6, 2026.

Is LLY stock expensive on P/E and P/S?

LLY trades at 43.0 times earnings and 15.4 times sales as of Nov 6, 2026.

What does LLY's seasonal forecast show?

ŷRobot's seasonal forecast curve for LLY reads +3.2% at 30 days, +7.8% at 90 days, and +27.0% at one year as of Nov 6, 2026. Seasonal tendencies are historical patterns, not predictions.

How fast is LLY growing?

Eli Lilly and Company's revenue growth is +28.0% and free-cash-flow growth is -0.4% on the latest reported figures.

Methodology & trust

What this is (and isn’t)

These outputs are generated by machine learning models trained on historical price, fundamental, and volume data. The models summarize historical data and current model outputs — they do not predict the future or constitute personalized investment advice. All figures are updated on a regular cadence and reflect the most recent available data at time of generation.

ŷRobot provides research and information, not personalized financial advice. Past performance is not a guarantee of future results.